[April 21, 2017 VIA EDGAR 100 F Street, N.E. Re: Notice of Disclosure Filed in Annual Report on Form 20-F Under Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 and Section 13(r) of the Exchange Act Ladies and Gentlemen: Respectfully submitted, CHINA UNICOM (HONG KONG) LIMI]
[FORM 20-F (Mark One) o OR x OR o OR o Date of event requiring this shell company report . . . . . . . . . . . . . . . . . . . For the transition period from to NETEASE, INC. N/A Cayman Islands (Jurisdiction of incorporation or organization) Building No. 7, West Zone, Zhongguancun] [SHAREHOLDER VOTIN]
[DATE OF BOARD MEETING The board (the “Board”) of directors of China Southern Airlines Company Limited (the “Company”) hereby announces that a Board meeting will be held on Friday, 28 April 2017 for the purpose of considering and approving, inter alia, the first quarterly results of the Company for t]
[Table of Contents Indicate the number of outstanding shares of each of the issuers classes of capital or common stock as of the close of the period covered by the annual report. 278,282,366 Ordinary Shares. x Yes o No o Yes x No x Yes o No x Yes o No Large accelerated filer x Accelerated filer o No]
[Yung Shun Loy Jacky Telephone: +852 2121 3220 Facsimile: +852 2121 3232 th 75 99 Queens Road Central Hong Kong (Name, Telephone, E-mail and/or Facsimile Number and Address of Company Contact person) Title of Each Class Name of Each Exchange On Which Registered Ordinary shares * None (Title of class]
[Schedule 14A ☒ ☐ Check the appropriate box: ☐ ☐ ☒ ☐ ☐ Biostar Pharmaceuticals, Inc. _____________________________________ Payment of Filing Fee (Check the appropriate box): ☒ ☐ (1) Title of each class of securities to which transaction applies: _____________________________ (2) Aggregate number of s]
[INTRODUCTION 1 1 PART I 3 ITEM 1 IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS 3 ITEM 2 OFFER STATISTICS AND EXPECTED TIMETABLE 3 ITEM 3 KEY INFORMATION 3 ITEM 4 INFORMATION ON THE COMPANY 38 ITEM 4A UNRESOLVED STAFF COMMENTS 70 ITEM 5 OPERATING AND FINANCIAL REVIEW AND PROSPECTS 70 ITEM 6 D]
[Number Page 1.1 Announcement, dated April 20, 2017 A-1]
[Schedule 14A ☒ ☐ Check the appropriate box: ☐ ☐ ☒ ☐ ☐ Biostar Pharmaceuticals, Inc. _____________________________________ Payment of Filing Fee (Check the appropriate box): ☒ ☐ (1) Title of each class of securities to which transaction applies: _____________________________ (2) Aggregate number of s]
[INTRODUCTION 1 1 PART I 3 ITEM 1 IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS 3 ITEM 2 OFFER STATISTICS AND EXPECTED TIMETABLE 3 ITEM 3 KEY INFORMATION 3 ITEM 4 INFORMATION ON THE COMPANY 38 ITEM 4A UNRESOLVED STAFF COMMENTS 70 ITEM 5 OPERATING AND FINANCIAL REVIEW AND PROSPECTS 70 ITEM 6 D]
